Studies at UToledo: Neurology
Epilepsy
Study Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures
Identifier: NCT03678753
Study Purpose: The purpose of this study is to evaluate the clinical efficacy and safety of cenobamate adjunctive therapy in PGTC seizures.
Principal Investigator: Naeem Mahfooz, MD
Study Coordinator:Joyeta Razzaque, MD, 419.383.4553
Huntington's Disease
Study Title: DIMENSION 718-CIH-201 A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants with Huntington's Disease
Identifier: NCT05655520
Study Purpose: The primary purpose of this study is to evaluate the tolerability and effectiveness of SAGE-718 on cognitive performance in study subjects with HD. The study will also evaluate the safety of SAGE-718, the effect on neuropsychiatric symptoms, and overall health-related quality of life.
Principal Investigator: Lawrence W. Elmer, MD, PhD
Study Coordinator:Nancy Vollmar, RN, 419.383.4573
Parkinson's
Study Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients with Dyskinesia to Asses the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and its Individual Components
Identifier: NCT04377945
Study Purpose: The purpose of this study is to assess the efficacy and safety/toelerability of fixed dose combinations of JM-010 and its individual components.
Principal Investigator: Thyagarajan Subramanian, MD
Study Coordinator:Joyeta Razzaque, MD, 419.383.4553
Study Title: A Multi-center, Noninterventional Study Evaluating Variability, Reliability and compliance for the Parkinson's Disease Diary.
Identifier: NCT05363046
Study Purpose: The purpose of this study is to evaluate the variability, reliability, and compliance for the PD Diary.
Principal Investigator: Thyagarajan Subramanian, MD
Study Coordinator:Joyeta Razzaque, MD, 419.383.4553
Study Title: Functional MRI Assessment of the Mental Rotation Task in Early Onset Parkinson's Disease Patients.
Identifier: Investigator initiated.
Study Purpose: Investigator initiated.
Principal Investigator: Thyagarajan Subramanian, MD
Study Coordinator:Joyeta Razzaque, MD, 419.383.4553
Study Title: Neuropsychological Tests to Assess Cognitive Differences in Early Onset Parkinson's Disease (EOPD) Patients.
Identifier: Investigator initiated.
Study Purpose: Investigator initiated.
Principal Investigator: Thyagarajan Subramanian, MD
Study Coordinator:Joyeta Razzaque, MD, 419.383.4553
Study Title: ACTIVATE A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects with Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene
Identifier: NCT05819359
Study Purpose: The primary purpose of this study is to investigate the effects, safety, and tolerability of BIA 28‑6156. This study is also meant to find out if the effects, safety, and tolerability are different in people with different forms of the GBA1 gene, which is a genetic characteristic that may be related to a higher risk of getting Parkinson’s disease, and if BIA 28-6156 can slow down the worsening of the disease.
Principal Investigator: Lawrence W. Elmer, MD, PhD
Study Coordinator:Stephanie Wilson, MSN, APRN, CCRC, 419.383.6721
Study Title: ATLANTIS A Multicenter Phase 2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of UCB0022 In Study Participants With Advanced Parkinson’s Disease.
Identifier: NCT06055985
Study Purpose: The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to a stable dose of concomitant PD medication (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced PD.
Principal Investigator: Lawrence W. Elmer, MD, PhD
Study Coordinator:Stephanie Wilson, MSN, APRN, CCRC, 419.383.6721